ArticleHaematologica2018

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

Niklas Landberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.